{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:31:17Z","timestamp":1793284277699,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032702","name":"Genmab A\/S","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100032702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,10]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG\n                      <jats:sub>1<\/jats:sub>\n                      antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. GEN3009 was assessed in non-clinical studies and a phase 1 dose-escalation study of B-cell non-Hodgkin\u2019s lymphoma (B-NHL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      After a non-clinical toxicity study was conducted in cynomolgus monkeys, a phase 1, first-in-human, open-label, multicenter dose-escalation trial of GEN3009 monotherapy enrolled adults with relapsed\/refractory (R\/R) B-NHL (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04358458\">NCT04358458<\/jats:ext-link>\n                      ). A modified Bayesian optimal interval design informed dose escalation and de-escalation with dose levels ranging from 6 mg to 2000\u2009mg. Primary endpoints were the rate of dose-limiting toxicities (DLTs) to determine the recommended phase 2 dose (RP2D) and safety and tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the toxicity study, 10\u2009mg\/kg GEN3009 weekly was identified as the highest non-severely toxic dose. In the phase 1 study, from March 13, 2020, to July 28, 2023, 46 patients with R\/R B-NHL received intravenous GEN3009 infusions. Median duration of treatment was 1.2 months (range, 0.0\u201314.5). No DLTs were observed up to 1600\u2009mg. The most common treatment-emergent adverse events were neutropenia (n=41 (89.1%)), infusion-related reactions (n=39 (84.8%)), and thrombocytopenia (n=18 (39.1%)). Plasma GEN3009 concentrations increased over time with increasing GEN3009 doses, with no apparent accumulation of GEN3009 observed over the course of treatment. Antitumor activity was observed at dose levels of \u2265180\u2009mg in both aggressive and indolent NHL. GEN3009 treatment reduced total hemolytic complement activity (CH50) levels in serum, and peak changes in CH50 levels were significantly correlated with clinical response (p=0.008 by Wilcoxon rank-sum test).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on safety, efficacy, and pharmacokinetics, the RP2D of GEN3009 was determined to be 1200\u2009mg. Preliminary data suggest that GEN3009 monotherapy demonstrated an acceptable safety profile at the RP2D of 1200\u2009mg, with modest clinical activity. These findings provide the first clinical proof-of-concept for hexamerization-potentiated molecules that induce antitumor activity through enhanced CDC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014311","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:25:20Z","timestamp":1783423520000},"page":"e014311","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04358458","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04358458","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T","family":"Awan","sequence":"first","affiliation":[{"name":"UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T","family":"Gamse","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije B","family":"Overdijk","sequence":"additional","affiliation":[{"name":"Genmab BV, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther C W","family":"Breij","sequence":"additional","affiliation":[{"name":"Genmab BV, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jure-Kunkel","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Sanghavi","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren K","family":"Brady","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijian","family":"Guan","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Verbrugge","sequence":"additional","affiliation":[{"name":"Genmab BV, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Chen","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Gong","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Genmab US Inc, Plainsboro, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tees","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute\/Sarah Cannon Research Institute, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Gallogly","sequence":"additional","affiliation":[{"name":"Seidman Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen, Denmark"},{"name":"University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Haaber","family":"Christensen","sequence":"additional","affiliation":[{"name":"Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia \u2013 L\u2019Hospitalet, IDIBELL, Barcelona, Spain"},{"name":"Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J Sherida H","family":"Woei-A-Jin","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roost Clausen","sequence":"additional","affiliation":[{"name":"Vejle Hospital, Vejle, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A","family":"Bhat","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Gopal","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center at UW Medical Center - Northwest, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine E D","family":"Chamuleau","sequence":"additional","affiliation":[{"name":"On behalf of the Lunenburg Lymphoma Phase I\/II Consortium-HOVON\/LLPC, Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026070704251101000_14.7.e014311.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"2026070704251101000_14.7.e014311.2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.157"},{"key":"2026070704251101000_14.7.e014311.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225397","article-title":"Changing trends in B-cell non-Hodgkin lymphoma treatment: the role of novel monoclonal antibodies in clinical practice","volume":"15","author":"Tavarozzi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070704251101000_14.7.e014311.4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted therapy in chronic lymphocytic leukemia","volume":"25","author":"Kipps","year":"2019","journal-title":"Cancer J"},{"key":"2026070704251101000_14.7.e014311.5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2026070704251101000_14.7.e014311.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026070704251101000_14.7.e014311.7","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1822318"},{"key":"2026070704251101000_14.7.e014311.8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"2026070704251101000_14.7.e014311.9","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2015.00091","article-title":"Tetraspanins as therapeutic targets in hematological malignancy: a concise review","volume":"6","author":"Beckwith","year":"2015","journal-title":"Front Physiol"},{"key":"2026070704251101000_14.7.e014311.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.3.905"},{"key":"2026070704251101000_14.7.e014311.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-505685"},{"key":"2026070704251101000_14.7.e014311.12","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10529-018-2612-6","article-title":"Anti-CD37 targeted immunotherapy of B-Cell malignancies","volume":"40","author":"Payandeh","year":"2018","journal-title":"Biotechnol Lett"},{"key":"2026070704251101000_14.7.e014311.13","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1427730"},{"key":"2026070704251101000_14.7.e014311.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062927"},{"key":"2026070704251101000_14.7.e014311.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512137"},{"key":"2026070704251101000_14.7.e014311.16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s10637-020-00916-3","article-title":"Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"38","author":"Kroschinsky","year":"2020","journal-title":"Invest New Drugs"},{"key":"2026070704251101000_14.7.e014311.17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Invest New Drugs"},{"key":"2026070704251101000_14.7.e014311.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0292-7","article-title":"DuoHexaBody-CD37\u00ae, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies","volume":"10","author":"Oostindie","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026070704251101000_14.7.e014311.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351932"},{"key":"2026070704251101000_14.7.e014311.20","doi-asserted-by":"crossref","DOI":"10.3390\/antib9040068","article-title":"Complement activation in the treatment of B-cell malignancies","volume":"9","author":"Zent","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"2026070704251101000_14.7.e014311.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"2026070704251101000_14.7.e014311.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900632"},{"key":"2026070704251101000_14.7.e014311.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.01.028"},{"key":"2026070704251101000_14.7.e014311.24","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000504","article-title":"Potent preclinical efficacy of DuoHexaBody-CD37 in B-cell malignancies","volume":"5","author":"van der Horst","year":"2021","journal-title":"Hemasphere"},{"key":"2026070704251101000_14.7.e014311.25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248943"},{"key":"2026070704251101000_14.7.e014311.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002344","article-title":"A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface","volume":"14","author":"de Jong","year":"2016","journal-title":"PLoS Biol"},{"key":"2026070704251101000_14.7.e014311.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0592"},{"key":"2026070704251101000_14.7.e014311.28","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314526475"},{"key":"2026070704251101000_14.7.e014311.29","doi-asserted-by":"crossref","unstructured":"Turnquist JE , Minugh-Purvis N . Functional morphology. In: Abee CR , Mansfield K , Tardif S , et al , eds. Nonhuman Primates in Biomedical Research. 2nd edn. New York, NY: Elsevier, 2012.","DOI":"10.1016\/B978-0-12-381365-7.00004-2"},{"key":"2026070704251101000_14.7.e014311.30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00261-015-0575-9","article-title":"Adrenal congestion preceding adrenal hemorrhage on CT imaging: a case series","volume":"41","author":"Tan","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"2026070704251101000_14.7.e014311.31","doi-asserted-by":"crossref","first-page":"105329","DOI":"10.1016\/j.yrtph.2022.105329","article-title":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","volume":"138","author":"Chien","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"2026070704251101000_14.7.e014311.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402414"},{"key":"2026070704251101000_14.7.e014311.33","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"2026070704251101000_14.7.e014311.34","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/s41375-019-0475-z","article-title":"Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed\/refractory chronic lymphocytic leukemia","volume":"33","author":"Stilgenbauer","year":"2019","journal-title":"Leukemia"},{"key":"2026070704251101000_14.7.e014311.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2026070704251101000_14.7.e014311.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:25:34Z","timestamp":1783423534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,7]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2025-014311"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014311","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}